Evotec SE (ETR:EVT – Get Free Report)’s share price passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of €2.87 and traded as low as €2.68. Evotec shares last traded at €2.75, with a volume of 1,808,363 shares changing hands.
Evotec Stock Performance
The firm’s 50-day moving average is €2.87 and its 200 day moving average is €4.21. The stock has a market cap of $506.17 million, a PE ratio of -2.95, a P/E/G ratio of 0.98 and a beta of 1.27. The company has a debt-to-equity ratio of 65.02, a quick ratio of 2.97 and a current ratio of 2.32.
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.
Featured Articles
- Five stocks we like better than Evotec
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
